Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
By Michel Bolla, L. Collette, L. Blank, P. Warde, J. Dubois, R. Mirimanoff, G. Storme, J. Bernier, A. Kuten, C. Sternberg and 6 more. The Lancet, 2002
1,738 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine, Radiation
View Paper: https://www.semanticscholar.org/paper/f47188de7c1d09adbfd48d4429a71d984822da2c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
- A. Heidenreich
- Michel Bolla
- N. Mottet
- J. Bellmunt
- V. Matveev
- Steven Joniau
- Celestia S. Higano
- F. Zattoni
Citations in the corpus
- Guidelines on Prostate Cancer (2013, background): “however, no trial has ever shown this approach to be superior to RP (49).”
- EAU guidelines on prostate cancer. (2001, background): “Therefore, neoadjuvant and adjuvant androgen deprivation for 2 yr is mandatory to significantly improve overall and cancer-specific survival [33,34].”